CDAK · Codiak Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | $22.93M | $2.92M |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| R&D | $64.86M | $73.98M |
| SG&A | $27.63M | $19.85M |
| Total Operating Expenses | $92.48M | $93.83M |
| D&A | $5.34M | $4.40M |
| Operating Income | ($69.55M) | ($90.92M) |
| Interest Expense | $2.70M | $1.91M |
| Income Tax | $0 | $0 |
| Net Income | ($37.16M) | ($91.67M) |
| EPS - Basic | - | - |
| EPS - Diluted | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Cash & Equivalents | $76.94M | $88.92M |
| Accounts Receivable | - | - |
| Inventory | - | - |
| Accounts Payable | $1.84M | $2.02M |
| Current Assets | $90.17M | $93.76M |
| Total Assets | $171.67M | $151.34M |
| Current Liabilities | $27.16M | $17.65M |
| Long-term Debt | - | - |
| Total Liabilities | $118.17M | $136.77M |
| Stockholders' Equity | $53.51M | $14.57M |
| Retained Earnings | ($325.25M) | ($288.09M) |
Cash Flow
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Operating Cash Flow | ($74.14M) | ($63.36M) |
| Investing Cash Flow | ($3.25M) | $52.01M |
| Financing Cash Flow | $65.41M | $89.58M |
| CapEx | $3.25M | $21.05M |
| Free Cash Flow | ($77.39M) | ($84.41M) |
Ratios
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Profitability | ||
| Gross margin | - | - |
| Operating margin | -303.2% | -3119.0% |
| EBITDA margin | -280.0% | -2968.0% |
| Net margin | -162.0% | -3144.6% |
| Free cash flow margin | -337.4% | -2895.8% |
| FCF / Net income | 2.08 | 0.92 |
| R&D / Revenue | 282.8% | 2537.9% |
| SG&A / Revenue | 120.5% | 681.0% |
| Effective tax rate | - | - |
| Return on assets | -21.6% | -60.6% |
| Return on equity | -69.4% | -629.3% |
| Return on invested capital | - | - |
| Liquidity | ||
| Current ratio | 3.32 | 5.31 |
| Quick ratio | 3.32 | 5.31 |
| Cash ratio | 2.83 | 5.04 |
| Leverage | ||
| Debt / Equity | - | - |
| Debt / Assets | - | - |
| Debt / EBITDA | - | - |
| Interest coverage | -25.8x | -47.7x |
| Equity multiplier | 3.21 | 10.39 |
| Liabilities / Assets | 0.69 | 0.90 |
| Efficiency | ||
| Asset turnover | 0.13 | 0.02 |
| Inventory turnover | - | - |
| Days sales outstanding | - | - |
| Days inventory outstanding | - | - |
| Days payable outstanding | - | - |
| Cash conversion cycle | - | - |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | 686.8% | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | - | - |
| Operating income growth (YoY) | 23.5% | - |
| Net income growth (YoY) | 59.5% | - |
| EPS growth (YoY) | - | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | 8.3% | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | 267.3% | - |
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
-2.28
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Codiak BioSciences against the 5 most active filers in the same SIC group.